Description

1. Product Overview: Imaxen 400® is a tyrosine kinase inhibitor containing Imatinib, used in the treatment of certain blood and solid tumors including chronic myeloid leukemia and gastrointestinal stromal tumors.

2. Composition: Imatinib Mesilate BP equivalent to Imatinib 400 mg | Dosage Form: Tablet

3. Pharmacological Class: Tyrosine Kinase Inhibitor (BCR-ABL, KIT, PDGFR inhibitor)

4. Mechanism of Action: Imatinib selectively inhibits abnormal tyrosine kinase enzymes such as BCR-ABL, KIT, and PDGFR, thereby blocking uncontrolled cell proliferation and inducing cancer cell death.

5. Indications: Chronic myeloid leukemia (CML) | Gastrointestinal stromal tumors (GIST) | Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) | Myeloproliferative disorders

6. Dosage & Administration: As directed by oncology specialist only | Oral use | Usually taken once daily with food and a full glass of water | Dose may vary based on condition

7. Clinical Benefits: Controls cancer cell growth | Improves survival in CML and GIST | Reduces disease progression | Effective targeted therapy

8. Contraindications: Hypersensitivity to Imatinib or any component of the formulation

9. Precautions: Liver function monitoring required | Risk of fluid retention and edema | Blood count monitoring necessary | Use cautiously in pregnancy

10. Drug Interactions: May interact with CYP3A4 inhibitors/inducers, warfarin, and certain antibiotics or antifungals

11. Special Populations: Not recommended during pregnancy unless clearly necessary | Lactation use under strict medical advice | Elderly patients require monitoring

12. Adverse Effects: Nausea | Edema | Muscle cramps | Fatigue | Rash | Diarrhea | Liver enzyme elevation

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.